Literature DB >> 3117592

Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval.

D de Ziegler1, M I Cedars, D Randle, J K Lu, H L Judd, D R Meldrum.   

Abstract

Five women with prior suboptimal ovarian stimulation for in vitro fertilization and embryo transfer (IVF-ET) were pretreated with a long-acting gonadotropin-releasing hormone (GnRH) agonist beginning in the midluteal phase of the preceding menstrual cycle. The four women with normal luteal function had castrate estrogen levels following regression of the corpus luteum, whereas one woman with an abnormal luteal phase and perimenopausal levels of gonadotropins had an agonistic response. In the three women with adequate stimulation, 20 oocytes were obtained and one women became pregnant. Initiation of GnRH agonist therapy during the luteal phase of a normal menstrual cycle may be an efficient way of obtaining ovarian suppression without an agonistic response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117592     DOI: 10.1016/s0015-0282(16)59535-1

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  15 in total

1.  Improved pregnancy outcome with gonadotropin releasing hormone agonist (GnRH-a) stimulation is due to the improvement in oocyte quantity rather than quality.

Authors:  H C Liu; Y M Lai; O Davis; A S Berkeley; M Graf; J Grifo; J Cohen; Z Rosenwaks
Journal:  J Assist Reprod Genet       Date:  1992-08       Impact factor: 3.412

Review 2.  Management of the poor responder: the role of GnRH agonists and antagonists.

Authors:  Eric S Surrey
Journal:  J Assist Reprod Genet       Date:  2007-11-29       Impact factor: 3.412

3.  Ovarian hyperstimulation associated with the sole use of leuprolide for ovarian suppression.

Authors:  J Yeh; R L Barbieri; V A Ravnikar
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-08

4.  Ovarian stimulation for in vitro fertilization using pure follicle-stimulating hormone with and without gonadotropin-releasing hormone agonist in high-responder patients.

Authors:  M C Edelstein; R G Brzyski; G S Jones; S Oehninger; S M Sieg; S J Muasher
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-06

5.  Ovarian suppression with leuprolide acetate: comparison of luteal, follicular, and flare-up administration in controlled ovarian hyperstimulation for oocyte retrieval.

Authors:  P R Gindoff; J L Hall; R J Stillman
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-04

6.  High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization.

Authors:  G E Hofmann; J P Toner; S J Muasher; G S Jones
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-10

7.  Does subtle progesterone rise on the day of HCG affect pregnancy rate in long agonist ICSI cycles?

Authors:  Hisham Ali Saleh; Mervat Sheikh El-Arab Omran; Mohamed Draz
Journal:  J Assist Reprod Genet       Date:  2009-05-21       Impact factor: 3.412

8.  The predictive value of serum progesterone and 17-OH progesterone levels on in vitro fertilization outcome.

Authors:  M J Levy; D B Smotrich; E A Widra; A W Sagoskin; D L Murray; J L Hall
Journal:  J Assist Reprod Genet       Date:  1995-03       Impact factor: 3.412

9.  The effect of leuprolide acetate on steroidogenesis by granulosa and theca cells in vitro.

Authors:  J L Frederick; M J Hickey; M M Francis; M V Sauer; R J Paulson
Journal:  J In Vitro Fert Embryo Transf       Date:  1991-08

Review 10.  Different ovarian stimulation protocols for women with diminished ovarian reserve.

Authors:  D Loutradis; P Drakakis; E Vomvolaki; A Antsaklis
Journal:  J Assist Reprod Genet       Date:  2007-11-22       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.